Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …
vaccination was implemented. We did a systematic review and meta-analysis of the …
[HTML][HTML] The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
C Patel, JML Brotherton, A Pillsbury… - …, 2018 - eurosurveillance.org
Background: A National human papilloma virus (HPV) Vaccination Programme for the
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
[HTML][HTML] The projected timeframe until cervical cancer elimination in Australia: a modelling study
Summary Background In 2007, Australia was one of the first countries to introduce a national
human papillomavirus (HPV) vaccination programme, and it has since achieved high …
human papillomavirus (HPV) vaccination programme, and it has since achieved high …
Very low prevalence of vaccine human papillomavirus types among 18-to 35-year old Australian women 9 years following implementation of vaccination
DA Machalek, SM Garland… - The Journal of …, 2018 - academic.oup.com
Introduction A quadrivalent human papillomavirus vaccination program targeting females
aged 12–13 years commenced in Australia in 2007, with catch-up vaccination of 14–26 year …
aged 12–13 years commenced in Australia in 2007, with catch-up vaccination of 14–26 year …
[HTML][HTML] Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic …
Summary Background Australia's National Cervical Screening Program currently
recommends cytological screening every 2 years for women aged 18–69 years. Human …
recommends cytological screening every 2 years for women aged 18–69 years. Human …
Eliminating cervical cancer: progress and challenges for high-income countries
Abstract In 2020, the World Health Organization launched a major initiative to eliminate
cervical cancer globally. The initiative is built around the three key pillars of human …
cervical cancer globally. The initiative is built around the three key pillars of human …
[HTML][HTML] Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV …
Background Using primary human papillomavirus (HPV) testing for cervical screening
increases detection of high-grade cervical intraepithelial neoplastic lesions and invasive …
increases detection of high-grade cervical intraepithelial neoplastic lesions and invasive …
Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors
PJ Woestenberg, AJ King… - The Journal of …, 2018 - academic.oup.com
Background Observational postmarketing studies are important to assess vaccine
effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine …
effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine …
[HTML][HTML] Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017–2035: example from Australia
Background Many countries are transitioning from cytology-based to longer-interval HPV
screening. Trials comparing HPV-based screening to cytology report an increase in CIN2/3 …
screening. Trials comparing HPV-based screening to cytology report an increase in CIN2/3 …
Hormonal contraceptive use and smoking as risk factors for high-grade cervical intraepithelial neoplasia in unvaccinated women aged 30–44 years: A case-control …
H Xu, S Egger, LS Velentzis, DL O'Connell, E Banks… - Cancer …, 2018 - Elsevier
Background Human papillomavirus (HPV) vaccines protect against HPV types 16/18, but do
not eliminate the need to detect pre-cancerous lesions. Australian women vaccinated as …
not eliminate the need to detect pre-cancerous lesions. Australian women vaccinated as …